发明授权
- 专利标题： KCNQ potassium channel agonist, and preparation method therefor and use thereof
-
申请号： US15870276申请日： 2018-01-12
-
公开(公告)号： US10316008B2公开(公告)日： 2019-06-11
- 发明人: Fajun Nan , Min Li , Zhaobing Gao , Yangming Zhang , Haining Hu , Haiyan Xu , Huanan Liu , Xiaoping Pi
- 申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
- 申请人地址： CN Shanghai
- 专利权人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
- 当前专利权人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
- 当前专利权人地址： CN Shanghai
- 代理机构： Morris, Manning & Martin, LLP
- 代理商 Ping Wang
- 优先权： CN201410175315 20140428
- 主分类号： C07D307/24
- IPC分类号： C07D307/24 ; A61K31/167 ; A61K31/17 ; A61K31/27 ; A61K31/277 ; A61K31/341 ; C07C269/04 ; C07C269/06 ; C07C271/28 ; C07C273/18 ; C07C275/64 ; C07C231/02 ; C07C333/08 ; C07C233/62 ; C07C235/16 ; C07C235/74 ; C07C237/04 ; C07C237/22 ; C07C237/48
摘要：
The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
公开/授权文献
信息查询
